These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21083186)

  • 21. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
    West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)
    Lancet; 2018 Apr; 391(10128):1378-1390. PubMed ID: 29606364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma.
    Hodel EM; Zanolari B; Mercier T; Biollaz J; Keiser J; Olliaro P; Genton B; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Apr; 877(10):867-86. PubMed ID: 19249251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria.
    McGready R; Stepniewska K; Lindegardh N; Ashley EA; La Y; Singhasivanon P; White NJ; Nosten F
    Eur J Clin Pharmacol; 2006 Dec; 62(12):1021-31. PubMed ID: 17053895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tailoring a Pediatric Formulation of Artemether-Lumefantrine for Treatment of Plasmodium falciparum Malaria.
    Bassat Q; Ogutu B; Djimde A; Stricker K; Hamed K
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4366-74. PubMed ID: 26014953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.
    Parikh S; Fehintola F; Huang L; Olson A; Adedeji WA; Darin KM; Morse GD; Murphy RL; Taiwo BO; Akinyinka OO; Adewole IF; Aweeka FT; Scarsi KK
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7852-6. PubMed ID: 26392500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria.
    Nyunt MM; Nguyen VK; Kajubi R; Huang L; Ssebuliba J; Kiconco S; Mwima MW; Achan J; Aweeka F; Parikh S; Mwebaza N
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1274-82. PubMed ID: 26666942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination of artemether and dihydroartemisinin in human plasma with a new hydrogen peroxide stabilization method.
    Huang L; Olson A; Gingrich D; Aweeka FT
    Bioanalysis; 2013 Jun; 5(12):1501-6. PubMed ID: 23795928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper.
    Blessborn D; Römsing S; Annerberg A; Sundquist D; Björkman A; Lindegardh N; Bergqvist Y
    J Pharm Biomed Anal; 2007 Oct; 45(2):282-7. PubMed ID: 17719735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand.
    Lefèvre G; Looareesuwan S; Treeprasertsuk S; Krudsood S; Silachamroon U; Gathmann I; Mull R; Bakshi R
    Am J Trop Med Hyg; 2001; 64(5-6):247-56. PubMed ID: 11463111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine.
    van Vugt M; Ezzet F; Nosten F; Gathmann I; Wilairatana P; Looareesuwan S; White NJ
    Am J Trop Med Hyg; 1999 Dec; 61(6):964-7. PubMed ID: 10674679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of an LC-MS method for the determination of artesunate and dihydroartemisinin plasma levels using liquid-liquid extraction.
    Van Quekelberghe SA; Soomro SA; Cordonnier JA; Jansen FH
    J Anal Toxicol; 2008 Mar; 32(2):133-9. PubMed ID: 18334096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP2B6*6 Genotype Specific Differences in Artemether-Lumefantrine Disposition in Healthy Volunteers.
    Abdullahi ST; Soyinka JO; Olagunju A; Bolarinwa RA; Olarewaju OJ; Bakare-Odunola MT; Winterberg M; Tarning J; Owen A; Khoo S
    J Clin Pharmacol; 2020 Mar; 60(3):351-360. PubMed ID: 31549442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased systemic exposures of artemether and dihydroartemisinin in infants under 5 kg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (Coartem®).
    Tiono AB; Tinto H; Alao MJ; Meremikwu M; Tshefu A; Ogutu B; Ouedraogo A; Lingani M; Cousin M; Lefèvre G; Jain JP; Duparc S; Hamed K
    Malar J; 2015 Apr; 14():157. PubMed ID: 25886021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous determination of artemether and its major metabolite dihydroartemisinin in plasma by gas chromatography-mass spectrometry-selected ion monitoring.
    Mohamed SS; Khalid SA; Ward SA; Wan TS; Tang HP; Zheng M; Haynes RK; Edwards G
    J Chromatogr B Biomed Sci Appl; 1999 Aug; 731(2):251-60. PubMed ID: 10510778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determination of lumefantrine in small-volume human plasma by LC-MS/MS: using a deuterated lumefantrine to overcome matrix effect and ionization saturation.
    Huang L; Li X; Marzan F; Lizak PS; Aweeka FT
    Bioanalysis; 2012 Jan; 4(2):157-66. PubMed ID: 22250798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial.
    Laman M; Moore BR; Benjamin JM; Yadi G; Bona C; Warrel J; Kattenberg JH; Koleala T; Manning L; Kasian B; Robinson LJ; Sambale N; Lorry L; Karl S; Davis WA; Rosanas-Urgell A; Mueller I; Siba PM; Betuela I; Davis TM
    PLoS Med; 2014 Dec; 11(12):e1001773. PubMed ID: 25549086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developmental toxicity studies of lumefantrine and artemether in rats and rabbits.
    Clark RL; Youreneff M; DeLise AM
    Birth Defects Res B Dev Reprod Toxicol; 2016 Dec; 107(6):243-257. PubMed ID: 28032463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Major pitfalls in the measurement of artemisinin derivatives in plasma in clinical studies.
    Lindegardh N; Hanpithakpong W; Kamanikom B; Singhasivanon P; Socheat D; Yi P; Dondorp AM; McGready R; Nosten F; White NJ; Day NP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Dec; 876(1):54-60. PubMed ID: 18980865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria.
    Wanzira H; Kakuru A; Arinaitwe E; Bigira V; Muhindo MK; Conrad M; Rosenthal PJ; Kamya MR; Tappero JW; Dorsey G
    Clin Infect Dis; 2014 Aug; 59(4):509-16. PubMed ID: 24825870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia.
    Denis MB; Tsuyuoka R; Lim P; Lindegardh N; Yi P; Top SN; Socheat D; Fandeur T; Annerberg A; Christophel EM; Ringwald P
    Trop Med Int Health; 2006 Dec; 11(12):1800-7. PubMed ID: 17176344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.